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1. Summary 
 
Chromatin remodelling and transcription factors play important roles in lineage 
commitment and development through control of gene expression. Activation of selected 
lineage-specific genes and repression of alternative lineage-affiliated genes results in tightly 
regulated cell differentiation transcriptional programmes. However, the complex functional 
and physical interplay between transcription factors and chromatin modifying enzymes 
remains elusive. Recent evidence has implicated histone demethylases in normal 
haematopoietic differentiation as well as in malignant haematopoiesis. Here we report an 
interaction between H3K4 demethylase JARID1A and the haematopoietic-specific master 
transcription proteins SCL and GATA1 in red blood cells. Specifically, we observe a direct 
physical contact between GATA1 and the second PHD domain of JARID1A. This 
interaction has potential implications for normal and malignant haematopoiesis. 
 
2. Introduction 
 
Epigenetic modifications, such as histone methylation, play critical roles in gene expression 
and regulate many cellular processes (Hyun et al. 2017). Histone lysine methylation is 
involved in transcriptional regulation through the combined action of histone methylases 
and demethylases. Specifically, methylated histone H3 lysine 4 (H3K4) marks contribute to 
active transcription, as emphasized by the observation that the three methylation states 
(H3K4me1, H3K4me2 and H3K4me3) mark actively transcribed genes. However, whilst a 
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clear correlation exists between H3K4 methylation and active transcription, less is known 
about how specific methyltransferases or demethylases are recruited to specific gene loci.  
JARID1A (also known as KDM5A or RBP2) belongs to the KDM5 family of histone 
demethylases. It is a ~200 kDa, ubiquitously expressed nuclear protein (Fattaey et al. 1993) 
that specifically demethylates tri- and di-methylated H3K4 (Christensen et al. 2007). Given 
the role of H3K4 methylation in activating transcription, it is thought that JARID1A acts as a 
transcriptional repressor through its chromatin demethylase activity. For example, studies 
have shown that JARID1A represses transcription in ES cells by binding to the promoter 
region of the homeobox genes Hoxa1, a5 and a7 (Christensen et al. 2007). Increasing evidence 
from primary tumours and model systems supports a role for the KDM5 family as 
oncogenic drivers (Rasmussen and Staller 2014), but their contribution to the mechanisms 
leading to malignant transformation remain poorly investigated. Indeed, although 
JARID1A was initially isolated based on its association with Retinoblastoma (Rb) tumour 
suppressor protein decades ago (Mao et al. 1997), its mechanistic role in oncogenesis is still 
unclear.  
Functionally, JARID1A is involved in normal and malignant haematopoiesis. Peripheral 
blood analysis of JARID1A knock-out mice showed neutrophilia, and analysis of their 
haematopoietic stem cell and myeloid compartments revealed a significant decrease in the 
rate of apoptosis as well as enhanced survival and cell cycling (Klose et al. 2007). Moreover, 
JARID1A has been identified as a fusion partner of Nucleoporin-98 (NUP98, a common 
fusion partner found in many leukaemias) in a subset of Acute Myeloid Leukaemia (AML) 
patients in which chromosomal translocation of NUP98 resulted in fusion of its amino 
terminus with the C-terminus PHD motif (PHD3) of JARID1A (van Zutven et al. 2006) 
(Fig.1). This fusion protein arrests haematopoietic differentiation in murine models and 
induces AML by abrogating the H3K4me3 binding potential of PHD3 finger (Wang et al. 
2009). NUP98/JARID1A fusion is found in about 11% of acute megakaryoblastic leukaemia 
(AMKL) patients, who, interestingly, also present overexpression of HOXA and HOXB gene 
clusters (de Rooij et al. 2013).  
As well as mediating fusion with NUP98, PHD3 is thought to mediate interactions of 
JARID1A to the LIM domain only 2 protein in Murine Erythroleukemia (MEL) cells (Mao et 
al. 1997). LMO2 is a member of the so-called LIM-only class of transcriptional co-regulators, 
which act as protein-protein adaptors and mediate interactions through their LIM domains 
(Chambers and Rabbitts 2015) (El Omari et al. 2011). LMO2 is a core component of a 
haematopoietic master transcriptional regulator complex known as the pentameric 
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complex, which also includes SCL/TAL1 and its heterodimerisation partner E47, LDB1 and 
GATA1 (Wadman et al. Embo 1997) (Fig.1). The crystal structure of the DNA-bound 
SCL/E47 basic helix-loop-helix (bHLH) heterodimer in complex with LMO2 fused to the 
LDB1 LIM interaction domain (LID) revealed complex synergies between components of 
the complex, their co-factors and DNA targets (El Omari et al. 2013).  
This complex is a key driver of gene expression programmes in both embryonic and adult 
haematopoiesis (Porcher et al. 2017). Emphasising its role in erythropoiesis, homozygous 
mutations of SCL/TAL1, LMO2 or GATA1 genes all result in embryonic lethality between 
days E9-E11.5 due to complete lack of formation of red blood cells (Warren et al. 1994; 
Shivdasani et al. 1995; Fujiwara et al. 1996). In T-cells, aberrant expression of SCL and 
LMO2 as a result of chromosomal translocation amongst other oncogenic processes is 
involved in the development of Acute Lymphoblastic Leukaemia (T-ALL) (Ferrando et al. 
2002; Correia et al. 2016). 
In the context of the pentameric complex, SCL serves both as a transcriptional activator and 
repressor in a context-dependent manner (Porcher et al. 2017). This dual activity results 
from recruitment of both coactivators, like acetyltransferases P300 and PCAF (Huang et al. 
1999; Huang et al. 2000), and corepressors such as ETO2, mSin3A, HDAC1/2 and LSD1 
(Huang and Brandt 2000; Schuh et al. 2005; Hu et al. 2009; Li et al. 2012). Specifically, 
phosphorylation-mediated dynamic recruitment of LSD1, another histone demethylase 
involved in removing monomethylated or dimethylated H3K4 (also called KDM1A), 
modulates SCL-directed transcription of target genes that are essential for haematopoietic 
progenitor differentiation (Li et al. 2012). Knockdown (KD) of LSD1 in haematopoietic 
progenitors impairs differentiation of multiple haematopoietic lineages, indicating that 
LSD1 has a critical role in haematopoiesis (Hu et al. 2009). Whilst much is known about the 
interactions of LSD1 with SCL, the role of other histone demethylases in this context has not 
been investigated.  
 Given the documented interactions of JARID1A with LMO2, JARID1A’s implication 
in AML and the fact that many protein partners of SCL, such as mSin3A and pRB (Huang 
and Brandt 2000; Vitelli et al. 2000) are also interaction partners of JARID1A (Defeo-Jones et 
al. 1991; van Oevelen et al. 2008), we set out to investigate a potential physical interaction 
between JARID1A and the pentameric protein complex to gain insights into JARID1A’s 
function in haematopoiesis. Our results indicate that in erythroid cells JARID1A associates 
with specific members of pentameric complex, including SCL and GATA1, and that it 
directly interacts with GATA1 through its second PHD domain. 
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3. Materials and Methods 
 
Cell culture 
 MEL (clone 585) cells were maintained in Dulbeccos modified Eagle medium-high 
glucose (Gibco) supplemented with 10% FCS, 100 U/ml penicillin, 100 µg/ml streptomycin 
and 2 mM L-glutamine. MEL cells differentiation was induced by addition of 2% DMSO 
followed by incubation at 37°C for 4 days.  
Nuclear extract preparations 
 For nuclear extract preparation, MEL cells were harvested by centrifugation at 
1000×g and washed once in 1×phosphate-buffered saline. Cell pellets were resuspended in 
chilled resuspension buffer (10 mM HEPES, pH 7.9, 1.5 mM MgCl2, 10 mM KCl, Complete 
EDTA free protease inhibitor (Roche), 1 mM dithiotreitol (DTT)). Cell suspension was 
incubated on ice for 10 minutes, mixed occasionally and vortexed for 10 seconds. The nuclei 
were pelleted by centrifugation for 1 minute at 16,300×g and resuspended in 20 mM 
HEPES, pH 7.9, 1.5 mM MgCl2, 420 mM NaCl, 25% glycerol, Complete EDTA free protease 
inhibitor (Roche), 1 mM DTT and incubated for 1 hour at 4°C on a rotary shaker. Nuclear 
extracts were obtained by centrifugation at 16,300×g for 5 minutes and supernatants 
aliquoted and stored at -80°C. 
 
Size exclusion chromatography 
 2.5 mg crude nuclear extracts isolated from MEL cells were subjected to fractionation 
on a Superose 6H/R column (Amersham Biosciences) equilibrated in 20 mM HEPES pH 7.9, 
200 mM NaCl, 1 mM DTT, 0.2 mM PMSF, 10% glycerol. 0.5 ml fractions were collected at a 
flow rate of 0.5 ml/min, precipitated with 72% Trichloroacetic acid and subjected to 
western blotting. 
Western blotting 
 Western blotting analysis was performed using NuPAGE precast gels (3-8% Tris-
acetate for JARID1A and 4-12% Bis-tris for SCL, GATA1, LMO2 and LDB1; Life 
Technologies) according to manufacturer’s instructions. Primary antibodies used were: 
JARID1A (ab70892; Abcam), SCL (sc-12984; Santa Cruz), LDB1 (sc-11198; Santa Cruz), 
LMO2 (MCA2744GA, ABD serotec) and GATA1 (sc-1234; Santa Cruz). Secondary 
antibodies used were horseradish peroxidase conjugated anti-goat/mouse/rabbit 
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immunoglobulin (Santa Cruz). Protein detection was carried out using ECL prime reagent 
kit (Amersham). 
Coimmunoprecipitations and immunoblot analysis  
 1 mg of nuclear extracts were diluted in dilution buffer (50 mM Tris, pH 7.5, 0.3% 
NP-40, protease inhibitor, 1 mM DTT) to attain a final concentration of 150 mM NaCl. 
Nuclear extracts were pre-cleared for 3 hours at 4°C by incubation with normal IgG (goat 
sc-2028 and rabbit sc-2027; Santa Cruz) and protein G Dynabeads (Life Technologies), 
blocked with 0.2 mg/ml BSA (Pierce) and 0.4 mg/ml sonicated salmon sperm DNA (Life 
Technologies). Immunoprecipitations were performed overnight at 4°C by incubation of the 
pre-cleared nuclear extracts with primary antibodies (for JARID1A, ab 70892; Abcam) and 
blocked protein G Dynabeads in dilution buffer (50 mM Tris, pH 7.5, 0.3% NP-40, protease 
inhibitor, 1 mM DTT). Beads were washed 5 times with 4×bed volume of wash buffer (50 
mM Tris, pH 7.5, 150 mM NaCl, 0.3% NP-40, protease inhibitor, 1 mM DTT) and bound 
material was eluted in 1×Laemmli buffer by boiling at 95°C for 10 minutes. Fractions were 
analysed by immunoblotting as described above. 
Cloning, expression and purification of JARID1A and GATA1 for Analytical 
ultracentrifugation 
 The three PHD domains of JARID1A (referred to as PHD1 (282-360), PHD2 (1156-
1222) and PHD3 (1608-1659) respectively in this paper) were amplified using JARID1A 
mouse cDNA (GeneArt) as template and primers 5’- 
aagttctgtttcagggcccgCGGAAGGGCACCCTGAGCG-3’/5’-
atggtctagaaagctttaCTCGCGCACGGCCTGCTC-3’ (for PHD1), 5’- 
aagttctgtttcagggcccgGAACGGATCGAGGAAGTGAAGTTCTGC-3’/5’- 
atggtctagaaagctttaTCTGGGCCGTCTGCTCCG-3’ (for PHD2) and 5’- 
aagttctgtttcagggcccgGCCGTGTGTGCCGCCCAG-3’/5’- 
atggtctagaaagctttaGGCGCAGTTGATGCAGATGTAGTCC3’ (for PHD3) and subsequently 
cloned using ligation independent In-fusion system (Clontech) into pOPINJ or pOPINF 
vectors (Berrow et al. 2007), encoding respectively either an N- terminal hexahistidine tag 
followed by a Glutathione S-transferase (GST) tag or only an N- terminal hexahistidine 
(His) tag . The human SCL(180-253)/E47 (535-613) bHLH was cloned, expressed and 
purified as described (El Omari et al. 2013). The human GATA1 construct (encoding N- and 
C- terminus fingers preceded by an N- terminal hexahistidine tag and referred to as 
GATA1NFCF (201-313) in this paper) was a generous gift from Dr. Olga Platonova.  
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The GST-Tag PHD1, PHD2 and PHD3 constructs were transformed into E.coli BL21 
cells for protein expression. Cells were grown at 37°C in Luria Broth (LB) until absorbance 
at 600 nm reached 0.6. This was followed by induction of protein expression by addition of 
1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) and growth at 20°C for 20h. Cell lysis 
was carried out in lysis buffer (50 mM HEPES, pH 8, 400 mM NaCl, 0.5% tween 20, 34 μl of 
sigma protease inhibitor, 12.5 units of DNaseI from Sigma) and the clarified lysate was 
mixed with glutathione beads. This was followed by overnight incubation at 4°C on a rotary 
shaker. Next day, beads were washed with the wash buffer (50 mM HEPES pH 8, 400 mM 
NaCl). The over-expressed protein was eluted using the elution buffer (50 mM HEPES, pH 
8, 200 mM NaCl and 15 mM reduced glutathione). The eluted protein fractions were 
concentrated using a concentrator (Millipore) with a Molecular weight cut-off (MWCO) 
appropriately chosen on the basis of the molecular weight of the protein. The concentrated 
proteins were further purified by size-exclusion chromatography, by loading on a HiLoad 
16/60 Superdex 75 prep grade column (GE Healthcare) in 50 mM HEPES pH 8, 200 mM 
NaCl, 1 mM DTT. 
 The PHD2 and GATA1NFCF constructs were transformed into E.coli Rosetta (DE3) 
pLysS cells for protein expression. Cells were grown at 37°C in LB until absorbance at 600 
nm reached 0.6. This was followed by induction of protein expression by addition of 1 mM 
IPTG and growth at 20°C for 16-20h. Cells transformed with plasmid encoding 
GATA1NFCF were grown in LB autoinduction media (Studier 2005) overnight at 37°C. 
Cells were harvested by centrifugation and resuspended in 50 mM HEPES pH 8, 400 mM 
NaCl, 10 mM Imidazole, 0.5% (v/v) Tween 20, Protease inhibitor and DNase I (for 
GATA1NFCF, lysis buffer was supplemented with 1 mM β-mercapto ethanol and 5 mM 
MgCl2). Cells were disrupted by sonication on ice and cell lysate clarified by centrifugation 
at 48,384×g. The clarified cell lysate was incubated with Talon affinity resin (Clontech) 
equilibrated with lysis buffer for an hour at 4°C. The beads were subsequently washed with 
10 bed volumes of 50 mM HEPES, pH 8, 400 mM NaCl, 10 mM Imidazole (for 
GATA1NFCF: 50 mM HEPES, pH 8, 400 mM NaCl, 30 mM Imidazole, 1 mM β-mercapto 
ethanol and 5 mM MgCl2) and the protein was eluted in 50 mM HEPES pH 8, 200 mM 
NaCl, 500 mM Imidazole (for GATA1NFCF, elution buffer was supplemented with 1 mM β-
mercapto ethanol and 5 mM MgCl2). The eluant was concentrated using protein 
concentrator (Millipore) of appropriate MWCO (3kDa for PHD2 and 10kDa for 
GATA1NFCF). Both the proteins were further purified by size exclusion chromatography 
using pre-equilibrated Superdex 75 (16/60) (GE Healthcare) in 50 mM HEPES pH 8, 200 
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mM NaCl, 1 mM DTT. The purified proteins were assessed by SDS-PAGE and concentrated 
to be used for Analytical ultracentrifugation. 
Analytical Ultracentrifugation 
 Analytical Ultracentrifugation sedimentation velocity experiments were performed 
using a Beckman Optima XL-I analytical ultracentrifuge operating in velocity mode at 20°C. 
All protein samples, at a molar concentration of 0.04 mM, were loaded onto a 3mm double 
sector-shaped centrepieces and spun at 29,024×g (An60Ti rotor, Beckman Coulter Inc., CA) 
with 150 sample distribution scans being taken with an interval of 6 minutes using 280 nm 
absorbance optics. The 10th to 120th scans were analysed using SedFit software (Brown and 
Schuck 2006) using continuous c(s) model to calculate the sedimentation coefficients of the 
sedimenting species at a resolution of 100 and also using c(s, f/f0) method at a resolution of 
10. The frictional coefficient is a unitless entity and is the ratio between the experimental 
frictional coefficient and the minimum frictional coefficient if the molecules in the sample 
were compact spheres (f/f0). Analysed data were then plotted using Pro Fit software 
(QuantumSoft; Uetikon am See, Switzerland) and fitted with a Gaussian function to 
determine peak centres, which represent the sedimentation coefficients of the species. 
Sedimentation coefficient (s) was plotted on X-axis, continuous sedimentation coefficient 
distribution (c(s)) on Y1-axis, molecular weight on Y2-axis and c(s,f/f0) was plotted over a 
third dimension which was represented by a heat plot. All the samples were in 50 mM 
HEPES pH 8, 200 mM NaCl and 1 mM DTT. 
 
4. Results 
 
JARID1A interacts with the pentameric complex in erythroid cells 
 We first interrogated the possible association between JARID1A and the pentameric 
complex in the cell line MEL, a well-established in vitro model of erythroid differentiation. 
Expression of endogenous JARID1A was detected in both undifferentiated MEL cells (D0, 
pro-erythroblast stage) and MEL cells undergoing terminal erythroid maturation (D2 and 
D4) (Fig. 2A). As SCL and protein partners are known to engage repressive activities in 
erythroid progenitors to prevent precocious lineage differentiation (Schuh et al. 2005; 
Porcher et al. 2017), we explored the relationship between JARID1A and the SCL complex 
in undifferentiated MEL cells. Nuclear extracts were derived from MEL cells and co-
immunoprecipitation experiments were performed with antibodies detecting endogenous 
proteins. Immunoprecipitation (IP) with antibodies against JARID1A followed by 
immunoblotting (IB) with antibodies against SCL, LMO2, LDB1 or GATA1 demonstrated 
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that JARID1A co-immunoprecipitated with SCL and GATA1 but not LMO2 or LDB1 (Fig. 
2B). Reciprocally, IP with antibodies against the components of the pentameric complex and 
IB with antibodies against JARID1A also revealed that SCL and GATA1, but not LDB1 or 
LMO2 coimmunoprecipitated with JARID1A(Fig.2C). This is in contrast to previously 
published findings where JARID1A was found to co-immunoprecipitated with in vitro 
translated radio-labelled LMO2 in MEL cells nuclear extracts (Mao et al. 1997). It is possible 
that weak interactions exist between LMO2 and JARID1A that can be detected by a more 
sensitive radioactive but not by chemiluminescent assay. Protein fractionation carried out 
from MEL cell nuclear extracts by fast protein liquid chromatography (FPLC) with a high 
salt extraction and size exclusion approach followed by western blotting shows JARID1A 
eluting in a number of fractions with a range of apparent molecular mass much greater than 
that of the monomeric protein (192kDa) suggesting that JARID1A may be part of a 
multiprotein complexes (Supplementary Fig.1). Although the elution pattern of JARID1A 
overlaps in many fractions with that of GATA1 and SCL, bands can also be seen for LMO2 
and LDB1 suggesting that the resolution of the technique does not allow an accurate 
delineation of the composition of such JARID1A containing complexes. 
 
JARID1A interacts directly with GATA1 
In order to determine the molecular basis for the interaction of JARID1A with members of 
the pentameric complex, we first carefully selected the domains of each of these proteins 
likely to be involved in protein/protein interactions based on previous reports. We then 
analysed interactions between the selected domains by Analytical UltraCentrifugation 
(AUC).  
JARID1A, like other KDM5 family members, possesses an atypical insertion of a 
DNA-binding ARID (AT rich) domain and a histone-binding PHD (PHD1) domain into the 
catalytic Jumonji domain, which separates it into two fragments (JmjN and JmjC) (Fig.1). It 
also contains two further C-terminal PHD domains (PHD2 and PHD3). PHD domains are 
structures known to mediate protein-protein interactions (Bienz 2006). In particular, 
JARID1A PHD3 has been studied in the context of its fusion with nucleoporin NUP98, 
where it has been shown to lose its binding to the H3K4 tri-methyl marks following fusion 
(van Zutven et al. 2006; Wang et al. 2009). The PHD1 domain preferentially recognizes 
unmethylated H3K4 histone tails, the product of JARID1A-mediated H3K4me3 
demethylation (Upadhyay et al. 2011). No function for the PHD2 domain has been reported 
to date and its ability to bind histone tails has not been probed. Separately, a number of 
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PHD domains have been identified that can also bind non-histone protein targets. For 
example, the PHD3 finger of MLL1 can associate with H3K4me2/3 and with the RNA 
recognition motif (RRM) of CyP33 using distinct binding pockets (Wang et al. 2010). 
Therefore, JARID1A PHD1-3 domains were selected for analysis.  
Previous functional and structural data indicate that SCL/E47 bHLH and GATA1 zinc-
finger domains mediate protein-protein interactions with ETO2/p300 (El Omari et al. 2013) 
and Fli-1/FOG-1 respectively (Tsang et al. 1997; Eisbacher et al. 2003) suggesting these 
domains as candidates for interaction with JARID1A. Additionally in the case of SCL, 
structure/function studies have shown that the bHLH domain alone can functionally 
rescue blood development in an Scl-null background (Porcher et al. 1999) thus 
strengthening its functional relevance. We thus focussed our analysis on the SCL/E47 
bHLH domain and GATA1 zinc fingers. 
AUC was used to probe direct interactions between GST-fused JARID1A PHD 
domains and either HIS-tagged SCL(180-253)/E47(535-613) bHLH domains (SCL/E47 
bHLH) or HIS-tagged GATA1 zinc-finger domains (GATA1NFCF) (201-313). We first 
determined the apparent sedimentation coefficients of GST PHD1 (282-360) and SCL/E47 
bHLH separately, which showed sedimentation coefficients of 3.8±0.09S and 1.9±0.04S 
respectively (Fig. 3A). An equimolar mixture of both proteins resulted in sedimentation 
coefficient peaks at 1.9±0.08S and 4.3±0.17S (Fig. 3A). The first peak corresponds to 
unbound SCL/E47 bHLH and while the second peak shows an increase in sedimentation 
coefficient. The model independent c(s,ff0) and molecular weight analysis shows three 
species at 1.8±0.27S, 3.9±0.2S, 4.5±0.2S representing unbound SCL/E47 bHLH, GST PHD1 
and complex respectively (Fig. 3D). The presence of three peaks suggests a mixture of 
different states and a dynamic interaction between SCL/E47 and GST PHD1. GST PHD2 
(1156-1222) and SCL/E47bHLH individually showed sedimentation coefficients values of 
3.8±0.20S and 1.8±0.10S respectively (Fig. 3B). When mixed in equimolar amounts, two well-
defined peaks at 1.8±0.10S and 3.8±0.19S can be observed, which overlap with the 
coefficients of the individual protein (Fig. 3B). This together with the model independent 
c(s,ff0) and molecular weight analysis (Fig. 3E) suggests no complex formation. Apparent 
sedimentation coefficient analysis of GST PHD3 (1608-1659) and SCL/E47 bHLH showed 
peaks at 3.6±0.07S and 1.9±0.06S respectively(Fig. 3C). When mixed in equimolar amounts, 
two well-defined peaks at 1.9±0.06S and 3.8±0.10S can again be observed (Fig. 3C). Together 
with the model independent c(s,ff0) and molecular weight analysis (Fig. 3F), they suggest no 
complex formation.  
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 Next, we investigated interactions between the zinc-finger domains of GATA1 and 
the PHD domains of JARID1A. We first determined the apparent sedimentation coefficients 
of GST PHD1 and GATA1NFCF separately, which showed values of 3.8±0.10S and 
1.5±0.06S (Fig. 4A). An equimolar mixture of the two proteins yielded two peaks with 
values of again 1.5±0.08S and 3.8±0.10S overlapping with the individual proteins’ peaks 
indicating no complex formation (Fig. 4A and 4D). GST PHD2 and GATA1NFCF separately 
displayed peaks at 3.9±0.10S and 1.5±0.06S respectively (Fig. 4B). When mixed in equimolar 
amounts, two well-defined peaks appeared at 1.5±0.10S and 4.0±0.30S (Fig. 4B). The first 
peak likely originates from unbound GATA1NFCF, while the second broader peak extends 
further than the sedimentation coefficient peak of GST PHD2 alone . This result, together 
with the model independent c(s,ff0) and molecular weight analysis (Fig. 4E), strongly 
suggests an interaction between GST PHD2 and GATA1NFCF. Finally, GST PHD3 and 
GATA1NFCF separately displayed peaks at 3.6±0.07S and 1.5±0.06S respectively (Fig. 4C). 
An equimolar mixture of the two proteins yielded two peaks overlapping with the 
individual protein peaks (Fig.4C) which together with the model independent c(s,ff0) and 
molecular weight analysis (Fig. 4F), suggests no complex formation between GST PHD3 
and GATA1NFCF. 
 To exclude any interference of the GST affinity tag, we further probed the 
interactions of a His-tag PHD2 domain of JARID1A. First, we used 15N HSQC NMR to 
probe the correct folding of the HIS-tag PHD2 construct. Well-dispersed, individual peaks 
can be distinguished in the 2D NMR spectrum (Supplementary Fig.2) suggesting a folded 
protein. We then used AUC to study the apparent sedimentation coefficients of His-tag 
PHD2 and GATA1NFCF. HIS-tagged PHD2 and GATA1NFCF separately showed 
sedimentation coefficients of 1.4±0.10S and 1.5±0.05S respectively (Fig. 5A). An equimolar 
mixture of both proteins showed a sedimentation coefficient peak at 1.7±0.06S, a shift that is 
highly suggestive of complex formation(Fig. 5A). The model independent c(s,ff0) and 
molecular weight analysis of absorbance data obtained from the equimolar mixture of 
PHD2 and GATA1NFCF resulted in two peaks (Fig. 5B). The first peak has a molecular 
weight of 15kDa probably originating from unbound GATA1NFCF while the second peak 
has a molecular weight of 20kDa, likely deriving from the complex.  
In conclusion, AUC experiments have revealed that the second PHD (PHD2) domain of 
JARID1A interacts directly with the zinc-finger domains of GATA1. Also, the data show 
that there is a possible direct interaction between the first PHD domain of JARID1A and the 
bHLH domains of SCL/E47, although this is likely to be highly dynamic in nature. As we 
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have probed the interactions of the PHD (1-3) domains of JARID1a and respectively the 
bHLH domains of SCL/E47 and zinc finger domains of GATA1, these experiments do not 
rule out interactions involving other parts of the proteins. 
 
5. Discussion 
 
Histone demethylase JARID1A is a recognised key factor for haematopoietic cell 
differentiation and proliferation and its disruption in the form of a fusion protein is 
prevalent in AML patients. Fusion proteins containing chromatin remodelling proteins 
often target histone-modifying activities to inappropriate genomic targets. An outstanding 
biological and mechanistic question is how JARID1A is normally targeted to the correct 
genomic loci.  
In this study, we report the interaction between JARID1A and members of the 
haematopoietic-specific pentameric protein complex (SCL and GATA1) in erythroid cells. 
When analysing putative interactions between known protein/protein interaction domains 
of JARID1A, SCL/E47 and GATA1, we show that this interaction could be directly 
mediated by GATA1 zinc finger domains and the second PHD domain (PHD2) of JARID1A 
(Fig.6C). Interestingly loss of both normal GATA1 and JARID1A function is linked with 
AMKL (Greene et al. 2003; de Rooij et al. 2013; Shand 2016), suggesting a possible functional 
link between loss of interaction and leukemogenesis.  
In conclusion, our data suggests that, in haematopoietic cells, JARID1A could be targeted to 
its genomic loci through interactions with a key component of the essential pentameric 
complex and thus participate in the control of expression of haematopoietic-specific genes 
and blood lineage differentiation. Further studies are required to elucidate whether 
JARID1A PHD2 domain is able to bind concomitantly histone tails and GATA1 and to 
further understand the functional relevance of JARID1A interaction with the SCL/GATA1 
pentameric complex in the context of normal and aberrant haematopoiesis. 
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Figure captions 
Figure 1. Schematic representation of JARID1A and SCL-GATA1 complex. (A) Schematic 
representation of the domains found in JARID1A, GATA1, SCL, E47, LDB1 and LMO2. 
JmjN- jumonji N, Arid- AT rich interacting domain, PHD- Plant homeo domain, JmjC- 
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jumonji C, ZF- zinc finger, bHLH- basic helix-loop-helix, LID- LIM interaction domain, 
LIM- Lin11/Isl1/Mec3 domain. The numbering for all proteins refers to the human 
sequence (B) Model of the SCL-GATA1 complex bound to DNA. 
 
Figure 2. Endogenous expression of JARID1A and coimmunoprecipitation of JARID1A, 
GATA1, SCL, LDB1 and LMO2. (A) JARID1A endogenous expression was checked at 
Day0 (D0),Day2 (D2) and Day4 (D4) of MEL cell differentiation by western blotting. Heat 
shock protein 70 (HSP 70) was used as loading control (B) Nuclear extracts from MEL cells 
were immunoprecipitated with JARID1A antibodies and the precipitated proteins were 
analysed by western blotting using antibodies shown. (C) Reverse coimmunoprecipitations 
were carried out on nuclear extracts from MEL cells with antibodies indicated and the 
precipitated proteins were analysed by western blotting. 
 
Figure 3. Biophysical studies of interaction between JARID1A and SCL/E37 by Analytical 
ultracentrifugation. AUC apparent sedimentation coefficient distribution profiles 
superimposed of(A) SCL/E47 bHLH (green), GST PHD1 (red) and SCL/E47 bHLH+ GST 
PHD1 (blue) (B) SCL/E47 bHLH (green), GST PHD2 (red) and SCL/E47 bHLH+ GST PHD2 
(blue) (C)  SCL/E47 bHLH (green), GST PHD3 (red) and SCL/E47 bHLH+GST PHD3 
(blue). C(s,ff0) and molecular weight analysis for (D) GST PHD1 and SCL/E47bHLH, (E) 
GST PHD2 and SCL/E47bHLH (F) GST PHD3 and SCL/E47 bHLH. The Y2 axis shows the 
estimated molecular weights and the temperature plot represents the distribution of the 
apparent frictional coefficients in the sample which is plotted over a third dimension (see 
key for contour plots). 
 
Figure 4. Biophysical studies of interaction between JARID1A and GATA1 by Analytical 
ultracentrifugation. AUC apparent sedimentation coefficient distribution profiles 
superimposed of(A) GATA1NFCF (green), GST PHD1 (red) and GATA1NFCF + GST PHD1 
(blue) (B) GATA1NFCF (green), GST PHD2 (red) and GATA1NFCF + GST PHD2 (blue) (C) 
GATA1NFCF (green), GST PHD3 (red) and GATA1NFCF +GST PHD3 (blue). C(s,ff0) and 
molecular weight analysis for (D) GST PHD1 and GATA1NFCF, (E) GST PHD2 and 
GATA1NFCF (F) GST PHD3 and GATA1NFCF. The Y2 axis shows the estimated molecular 
weights and the temperature plot represents the distribution of the apparent frictional 
coefficients in the sample which is plotted over a third dimension (see key for contour 
plots). 
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Figure 5. Biophysical studies of interaction between PHD2 domain of JARID1A and 
GATA1 by Analytical ultracentrifugation. (A) AUC apparent sedimentation coefficient 
distribution profiles of HIS-PHD2 (red), GATA1NFCF (green) and HIS-
PHD2+GATA1NFCF (blue) superimposed. (B) c(s,ff0) and molecular weight analysis for 
HIS-PHD2+GATA1NFCF. The Y2 axis shows the estimated molecular weights and the 
temperature plot represents the distribution of the apparent frictional coefficients in the 
sample which is plotted over a third dimension (see key for contour plots).  
 
Supplementary Figure1. Co-fractionation of JARID1A with the SCL-GATA1 complex by 
size exclusion chromatography. Nuclear extracts from MEL cells were fractionated using 
Superose 6 size exclusion column. The elution fractions were analysed by Western blotting 
Western blotting analysis was performed using NuPAGE precast gels (3-8% Tris-acetate for 
JARID1A and 4-12% Bis-tris for SCL, GATA1, LMO2 and LDB1; Life Technologies) 
according to manufacturer’s instructions. Primary antibodies used were: JARID1A 
(ab70892; Abcam), SCL (sc-12984; Santa Cruz), LDB1 (sc-11198; Santa Cruz), LMO2 
(MCA2744GA, ABD serotec) and GATA1 (sc-1234; Santa Cruz). Chromatography profile 
and western blot analysis are shown. The elution positions of the molecular weight 
standards (669, 440, 158, 43, 13.7 kDa) and that of the void volume are indicated above the 
chromatogram.  
 
Supplementary Figure2. 500 MHz 1H–15N HSQC spectrum of JARID1A PHD2. 
15Nsingle- labelled His-Tag PHD2 was grown in M9 minimal media containing 15N–
NH4Cl (1 g/L) (Sigma-Aldrich) as sole nitrogen source and purified as described in the 
Materials and Methods section. 15N -labelled sample of His-Tag PHD2 was probed in 20 
mM NaH2PO4 pH 7.0 (95% H2O/ 5% D2O (v/v)), 100 mM NaCl at a concentration of 57.9 
μM. NMR experiments were carried out at 293 K using a 500 MHz spectrometer equipped 
with Bruker Avance console and TCI CryoProbe. 
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